Table 2.
Observed and expected second and higher order primary cancers over the entire 335 436 patient-years of follow-up from 6 months after diagnosis to 10 years follow-up or the 31 December 2014, overall, by subsite of first primary lung cancer and by patient characteristics. Italics denotes the lung sub-sites
| Observed SPCs | Expected SPCs | Absolute incidence rate per 100 000 person-years | Standardised incidence rate ratio | ||||
| Estimate | (95% CI) | Estimate | (95% CI) | ||||
| Overall | 2313 | 1491.9 | 689.6 | (661.7 to 718.2) | 1.55 | (1.49 to 1.61) | |
| Subsite of first primary lung cancer | Small cell carcinoma | 131 | 109.0 | 455.3 | (380.7 to 540.2) | 1.20 | (1.00 to 1.43) |
| Adenocarcinoma | 759 | 407.0 | 752.4 | (699.8 to 807.9) | 1.86 | (1.73 to 2.00) | |
| Squamous cell carcinoma (SCC) | 873 | 497.9 | 882.8 | (825.2 to 943.3) | 1.75 | (1.64 to 1.87) | |
| Other NSCLC | 312 | 223.0 | 619.4 | (552.6 to 692.1) | 1.40 | (1.25 to 1.56) | |
| Carcinoid | 31 | 41.7 | 219.4 | (149.1 to 311.4) | 0.74 | (0.51 to 1.06) | |
| Unspecified lung | 207 | 213.2 | 488.3 | (424.0 to 559.5) | 0.97 | (0.84 to 1.11) | |
| Site of SPC | Lung | 1460 | 993.8 | 435.3 | (413.2 to 458.2) | 1.47 | (1.39 to 1.55) |
| Small cell carcinoma | 142 | 94.3 | 42.3 | (35.7 to 49.9) | 1.51 | (1.27 to 1.78) | |
| NSCLC | 1318 | 899.5 | 392.9 | (372.0 to 414.7) | 1.47 | (1.39 to 1.55) | |
| Adenocarcinoma | 485 | 187.8 | 144.6 | (132.0 to 158.0) | 2.58 | (2.36 to 2.82) | |
| Squamous cell carcinoma | 400 | 190.9 | 119.2 | (107.8 to 131.5) | 2.10 | (1.90 to 2.31) | |
| Other NSCLC | 216 | 143.5 | 64.4 | (56.1 to 73.6) | 1.51 | (1.31 to 1.72) | |
| Carcinoid | 13 | 4.4 | 3.9 | (2.1 to 6.6) | 2.98 | (1.59 to 5.10) | |
| Unspecified lung | 204 | 372.9 | 60.8 | (52.8 to 69.8) | 0.55 | (0.47 to 0.63) | |
| Bladder | 397 | 299.9 | 118.4 | (107.0 to 130.6) | 1.32 | (1.20 to 1.46) | |
| Oesophageal SCC | 124 | 52.1 | 37.0 | (30.7 to 44.1) | 2.38 | (1.98 to 2.84) | |
| Laryngeal | 122 | 43.5 | 36.4 | (30.2 to 43.4) | 2.81 | (2.33 to 3.35) | |
| Head and neck | 210 | 102.6 | 62.6 | (54.4 to 71.7) | 2.05 | (1.78 to 2.34) | |
| Age at diagnosis | 30–49 | 59 | 17.5 | 316.1 | (240.6 to 407.8) | 3.38 | (2.57 to 4.35) |
| 50–59 | 332 | 121.0 | 608.3 | (544.6 to 677.3) | 2.74 | (2.46 to 3.05) | |
| 60–69 | 862 | 428.0 | 779.0 | (727.8 to 832.7) | 2.01 | (1.88 to 2.15) | |
| 70–79 | 833 | 658.9 | 751.4 | (701.2 to 804.2) | 1.26 | (1.18 to 1.35) | |
| 80–99 | 227 | 266.4 | 558.1 | (487.9 to 635.6) | 0.85 | (0.74 to 0.97) | |
| Sex | Male | 1398 | 1030.7 | 792.7 | (751.7 to 835.4) | 1.36 | (1.29 to 1.43) |
| Female | 915 | 461.1 | 575.2 | (538.5 to 613.7) | 1.98 | (1.86 to 2.12) | |
| Deprivation quintile | 1-least deprived | 315 | 234.4 | 616.1 | (549.9 to 688.0) | 1.34 | (1.20 to 1.50) |
| 2 | 391 | 273.5 | 653.7 | (590.5 to 721.8) | 1.43 | (1.29 to 1.58) | |
| 3 | 464 | 303.2 | 688.4 | (627.2 to 754.0) | 1.53 | (1.39 to 1.68) | |
| 4 | 492 | 325.1 | 663.9 | (606.5 to 725.2) | 1.51 | (1.38 to 1.65) | |
| 5 - most deprived | 651 | 355.6 | 784.5 | (725.4 to 847.2) | 1.83 | (1.69 to 1.98) | |
| Period of first diagnosis | 2000–2004 | 762 | 535.8 | 633.3 | (589.2 to 680.0) | 1.42 | (1.32 to 1.53) |
| 2005–2009 | 941 | 575.2 | 724.6 | (679.1 to 772.5) | 1.64 | (1.53 to 1.74) | |
| 2010–2014 | 610 | 380.9 | 715.4 | (659.8 to 774.5) | 1.60 | (1.48 to 1.73) | |
| Elapsed follow-up time | 6–12 months | 390 | 450.9 | 401.4 | (362.5 to 443.3) | 0.87 | (0.78 to 0.96) |
| 1–5 years | 1302 | 804.8 | 698.9 | (661.4 to 737.9) | 1.62 | (1.53 to 1.71) | |
| 5–10 years | 621 | 236.2 | 1194.9 | (1102.7 to 1292.6) | 2.63 | (2.43 to 2.84) | |